{"id":"NCT00920439","sponsor":"GlaxoSmithKline","briefTitle":"Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' IPV Vaccine (PoliorixTM) in Toddlers","officialTitle":"An Open-label Study to Assess the Safety and Reactogenicity of GlaxoSmithKline Biologicals' Inactivated Poliomyelitis Vaccine Poliorix Administered as a Booster Dose at 18-24 Months of Age in Healthy Toddlers in China.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06-01","primaryCompletion":"2009-08-03","completion":"2009-08-03","firstPosted":"2009-06-15","resultsPosted":"2017-10-19","lastUpdate":"2018-01-19"},"enrollment":26,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Poliomyelitis"],"interventions":[{"type":"BIOLOGICAL","name":"PoliorixTM","otherNames":[]}],"arms":[{"label":"POLIORIX GROUP","type":"EXPERIMENTAL"}],"summary":"The study will evaluate the safety and reactogenicity of PoliorixTM given as a single booster dose to Chinese children at 18-24 months of age.","primaryOutcome":{"measure":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","timeFrame":"During the 4-day (Days 0-3) post-vaccination period","effectByArm":[{"arm":"Poliorix Group","deltaMin":4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":5,"exclusionCount":11},"locations":{"siteCount":1,"countries":["China"]},"refs":{"pmids":["26873055"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Pyrexia","Erythema","Irritability","Pain","Decreased appetite"]}}